Opko Health, Inc. (NASDAQ:OPK) CEO Acquires $30,250.00 in Stock

Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 5,000 shares of the firm’s stock in a transaction on Tuesday, August 8th. The shares were acquired at an average cost of $6.05 per share, with a total value of $30,250.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $18,567,153.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Thursday, August 10th, Phillip Md Et Al Frost purchased 39,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.23 per share, with a total value of $242,970.00.
  • On Wednesday, August 9th, Phillip Md Et Al Frost purchased 18,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.35 per share, with a total value of $114,300.00.
  • On Wednesday, August 2nd, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.15 per share, with a total value of $153,750.00.
  • On Tuesday, August 1st, Phillip Md Et Al Frost purchased 46,600 shares of Opko Health stock. The shares were acquired at an average cost of $6.25 per share, with a total value of $291,250.00.
  • On Friday, July 28th, Phillip Md Et Al Frost purchased 35,100 shares of Opko Health stock. The shares were acquired at an average cost of $6.30 per share, with a total value of $221,130.00.
  • On Thursday, July 27th, Phillip Md Et Al Frost purchased 23,600 shares of Opko Health stock. The shares were acquired at an average cost of $6.34 per share, with a total value of $149,624.00.
  • On Wednesday, July 26th, Phillip Md Et Al Frost purchased 36,200 shares of Opko Health stock. The shares were acquired at an average cost of $6.39 per share, with a total value of $231,318.00.
  • On Tuesday, July 25th, Phillip Md Et Al Frost purchased 39,800 shares of Opko Health stock. The shares were acquired at an average cost of $6.41 per share, with a total value of $255,118.00.
  • On Monday, July 24th, Phillip Md Et Al Frost purchased 45,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.42 per share, with a total value of $288,900.00.
  • On Thursday, July 20th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The shares were acquired at an average cost of $6.46 per share, with a total value of $34,884.00.

Opko Health, Inc. (NASDAQ OPK) traded up 2.13% during mid-day trading on Friday, hitting $6.24. The stock had a trading volume of 4,707,786 shares. The company has a 50-day moving average of $6.38 and a 200-day moving average of $7.28. The firm’s market cap is $3.49 billion. Opko Health, Inc. has a 12-month low of $5.99 and a 12-month high of $12.15.

Opko Health (NASDAQ:OPK) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. Opko Health had a negative net margin of 6.52% and a negative return on equity of 3.67%. The firm had revenue of $314.20 million for the quarter, compared to analysts’ expectations of $322.64 million. During the same quarter last year, the company posted $0.02 earnings per share. Opko Health’s revenue was down 12.0% on a year-over-year basis. Analysts expect that Opko Health, Inc. will post ($0.20) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.thestockobserver.com/2017/08/12/opko-health-inc-nasdaqopk-ceo-acquires-30250-00-in-stock.html.

A number of institutional investors have recently modified their holdings of OPK. Financial Architects Inc boosted its position in shares of Opko Health by 45.0% in the second quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock worth $102,000 after buying an additional 4,800 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Opko Health during the fourth quarter worth about $105,000. Blair William & Co. IL acquired a new position in shares of Opko Health during the second quarter worth about $112,000. Timber Hill LLC acquired a new position in shares of Opko Health during the first quarter worth about $114,000. Finally, Comerica Bank acquired a new position in shares of Opko Health during the fourth quarter worth about $117,000. 23.05% of the stock is currently owned by hedge funds and other institutional investors.

OPK has been the subject of a number of recent analyst reports. BidaskClub raised Opko Health from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $19.50 target price on shares of Opko Health in a report on Friday, June 16th. Zacks Investment Research downgraded Opko Health from a “buy” rating to a “hold” rating in a report on Saturday. Jefferies Group LLC reissued a “hold” rating and issued a $6.50 target price (down from $6.80) on shares of Opko Health in a report on Thursday. Finally, Barrington Research boosted their target price on Opko Health to $11.00 and gave the company an “outperform” rating in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. Opko Health has an average rating of “Hold” and an average price target of $14.61.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply